Brain Cancer Vaccine Gets Positive Phase 2 Results

Agenus Inc. today announced that a recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme (GBM) treated with Prophage Series G-100 (HSPPC-96) in combination with the current standard of care (radiation and temozolomide) showed an almost 18 month median progression free survival (PFS), which represents a 160% increase versus current standard of care alone. This analysis confirms continuation of the positive trends from the Phase 2 HSPPC-96 newly diagnosed GBM trial first reported at the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in May 2013.   

 “These additional results from the Phase 2 trial of HSPPC-96 in patients with newly diagnosed GBM are extremely encouraging and certainly justify a definitive randomized study,” said Andrew T. Parsa, MD, PhD, lead clinical investigator and chair of Neurosurgery at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine. “The patient-specificity and lack of toxicity, combined with patient selection to optimize immunotherapy efficacy, could position this vaccine as a break-through treatment for newly diagnosed GBM patients in the years ahead.”  Based on these findings, Agenus plans to hold an end of Phase 2 meeting with the US Food and Drug Administration (FDA) to discuss a Phase 3 trial that could potentially lead to marketing approval of the HSPPC-96 vaccine as a treatment for patients with newly diagnosed GBM. Click here to view the full press release from Agenus.

Share |
November 18, 2014 12:33 PM
Accelerate Brain Cancer Cure funded Duke University's early work on the vaccine.
November 7, 2014 02:28 PM
Proceeds to benefit Accelerate Brain Cancer Cure.
November 6, 2014 02:51 PM
Second Brain Tumor Clinical Trial Endpoints Workshop identified steps needed to include measures of patient signs, symptoms, and function as part of evaluation of therapy benefit.

Join us in our fight for a cure!

Twitter